Showing results (1-10 of 484) with videos related to
Sort By:
Pageof 49
Bulletin Du Cancer|August 9, 2011
[Hypomethylating agents for the treatment of myelodysplastic syndromes]Raphael Itzykson, Pierre FenauxCurrent Opinion in Hematology|May 27, 2009
Optimal sequencing of treatments for patients with myelodysplastic syndromesRaphael Itzykson, Pierre FenauxCurrent Opinion in Hematology|January 18, 2012
Optimizing hypomethylating agents in myelodysplastic syndromesRaphael Itzykson, Pierre FenauxLancet (London, England)|March 25, 2014
Myelodysplastic syndromesLionel Adès, Raphael Itzykson, Pierre FenauxSeminars in Hematology|October 20, 2012
Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidineLionel Adès, Raphael Itzykson, Pierre FenauxBest Practice & Research. Clinical Haematology|February 11, 2014
Somatic mutations and epigenetic abnormalities in myelodysplastic syndromesRaphael Itzykson, Olivier Kosmider, Pierre FenauxBest Practice & Research. Clinical Haematology|February 11, 2014
Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?Raphael Itzykson, Raphael Itzkson, Pierre Fenaux, et al.Best Practice & Research. Clinical Haematology|May 29, 2020
Contemporary treatment approaches to CMML - Is allogeneic HCT the only cure?Marie Robin, Raphael ItzyksonInternational Journal of Hematology|April 26, 2019
Clinical update on hypomethylating agentsMatthieu Duchmann, Raphael ItzyksonPageof 49